Heritable Pulmonary Arterial Hypertension

1. Disease Information

1.1 What is the disease? (concise overview)

PAH is described as a rare, severe pulmonary vascular disorder with obliteration/remodeling of pulmonary microvessels causing increased PVR, progressive elevation of pulmonary artery pressure, RV hypertrophy and failure (eichstaedt2023geneticcounsellingand pages 1-2). In the ERS genetics consensus statement, HPAH is defined as including familial PAH and sporadic PAH when an underlying (likely) pathogenic variant in a PAH-predisposing gene is present (eichstaedt2023geneticcounsellingand pages 2-3).

1.2 Key identifiers (ontology/clinical coding)

The current evidence corpus directly supports the following ontology identifiers:

Table: This table summarizes the key disease names, identifiers, and classification terms for heritable pulmonary arterial hypertension that were explicitly supported in the retrieved evidence. It is useful for normalizing nomenclature and ontology mappings for a disease knowledge base entry.

Gaps: Orphanet, OMIM, ICD-10/ICD-11, and MeSH identifiers were not retrievable from the tool-accessible sources in this run, and are therefore not reported (to avoid unverified assertions).

1.3 Common synonyms / alternative names

Evidence-supported synonyms and related terms include: - “Familial PAH (FPAH)” in the context of heritable disease (eichstaedt2023geneticcounsellingand pages 2-3). - Historical terminology: idiopathic PAH previously termed “primary pulmonary hypertension (PPH)” (eichstaedt2023geneticcounsellingand pages 2-3).

1.4 Evidence source type (individual vs aggregated)

Key statements in this report draw primarily from aggregated disease-level resources (WSPH/ERS task-force reports and consensus statements) and cohort-based human studies, supplemented with animal and in vitro experimental model studies (kovacs2024definitionclassificationand pages 15-17, eichstaedt2023geneticcounsellingand pages 2-3, wang2024hemodynamicandclinical pages 1-3, todesco2024pulmonaryhypertensioninduced pages 1-2, wang2023dysregulatedsmoothmuscle pages 1-3).

2. Etiology

2.1 Disease causal factors

Primary cause: Pathogenic germline variants in PAH-predisposition genes, most commonly BMPR2, with autosomal dominant inheritance and incomplete penetrance (eichstaedt2023geneticcounsellingand pages 3-4, li2024bonemorphogeneticprotein pages 1-2). BMPR2 variants predispose to small pulmonary artery narrowing by “driving cell proliferation and preventing apoptosis,” producing vascular remodeling with smooth muscle and fibroblast proliferation, neointimal lesions and plexiform lesions (eichstaedt2023geneticcounsellingand pages 2-3).

Current gene set: A 2024 WSPH/ERS definition/classification report cites an international expert panel classifying 12 genes with “definitive evidence” for PAH gene–disease relationship: BMPR2, ACVRL1, ATP13A3, CAV1, EIF2AK4, ENG, GDF2, KCNK3, KDR, SMAD9, SOX17, TBX4 (kovacs2024definitionclassificationand pages 15-17).

2.2 Risk factors

Genetic risk factors (causal variants)

• BMPR2: most prevalent disease gene; “found in over 80% of heritable cases” (abstract quote) (li2024bonemorphogeneticprotein pages 1-2). BMPR2 mutations are also found in ~17% of idiopathic PAH (li2024bonemorphogeneticprotein pages 1-2).
• Sex-dimorphic penetrance in BMPR2 carriers: penetrance estimated ~30% overall with 42% of heterozygous women and 14% of heterozygous men developing PAH (eichstaedt2023geneticcounsellingand pages 3-4).
• PVOD/PCH genetics (important differential): heritable PVOD/PCH is autosomal recessive due to biallelic EIF2AK4 pathogenic variants; biallelic EIF2AK4 variants represent at least 25% of PVOD/PCH cases (eichstaedt2023geneticcounsellingand pages 3-4).

Environmental / clinical “second hits” (gene–environment / gene–trigger interactions)

Multiple experimental and conceptual frameworks support the idea that incomplete penetrance implies additional triggers. In a 2024 BMPR2 rat model paper, the authors state: “The incomplete penetrance of BMPR2 mutations implies that additional triggers are necessary” (abstract quote) (todesco2024pulmonaryhypertensioninduced pages 1-2). Second-hit triggers used in BMPR2 models include hypoxia, inflammation (e.g., LPS), serotonin, monocrotaline, and surgical flow redistribution (RPA occlusion) (todesco2024pulmonaryhypertensioninduced pages 1-2).

2.3 Protective factors

Direct, evidence-backed protective factors for HPAH were not explicitly identified in the retrieved sources. One cohort study suggested “GDF2 may be a protective or corrected modifier in certain genetic backgrounds” (abstract quote) based on observed differences in circulating GDF2 in variant carriers, but this is hypothesis-generating rather than definitive protection (wang2024hemodynamicandclinical pages 1-3).

3. Phenotypes

Evidence-supported phenotypes, diagnostic features, and quantitative cohort data are summarized here:

Table: This table compiles evidence-backed clinical phenotypes, diagnostic criteria, screening tools, and epidemiology relevant to heritable pulmonary arterial hypertension. It is useful for rapid disease knowledge-base population because it pairs quantitative findings with ontology suggestions and direct evidence sources.

3.1 Phenotype characteristics (selected)

• Age of onset: Variable; gene-specific early onset noted for ACVRL1-associated PAH with median onset 20 years in the HHT/ACVRL1 context (eichstaedt2023geneticcounsellingand pages 3-4).
• Sex bias: Female predominance 70–80% overall across PAH registries, with variation by subgroup (eichstaedt2023geneticcounsellingand pages 2-3).
• Severity/progression: BMPR2 pathogenic variant carriers have younger onset and a more compromised hemodynamic profile and higher risk of death or lung transplantation (eichstaedt2023geneticcounsellingand pages 3-4).

3.2 Quality of life impact

Quality-of-life metrics (e.g., EQ-5D, SF-36) were not directly retrievable in the present evidence set. Functional limitation is indirectly supported through 6-minute walk distance (6MWD) and WHO functional class distributions in a 2024 cohort (wang2024hemodynamicandclinical pages 1-3).

4. Genetic / Molecular Information

4.1 Causal genes (definitive list)

Table: This table summarizes the HPAH-definitive or clearly supported genes, their functional classes, inheritance notes, and the main quantitative facts retrievable from the current evidence corpus. It is useful for quickly populating a disease knowledge base with high-confidence gene-level information while distinguishing classic HPAH genes from EIF2AK4-associated PVOD/PCH.

4.2 Pathogenic variants: classes and examples

• The ERS genetics consensus notes “More than 800 different, independent pathogenic BMPR2 variants” have been identified (eichstaedt2023geneticcounsellingand pages 2-3).
• A Taiwanese idiopathic/heritable PAH cohort (n=69; WES) reported BMPR2 variant types including nonsense, missense, and an in-frame deletion; example BMPR2 variants: c.994C>T (p.Arg332*), c.1750C>T (p.Arg584*), c.1478C>T (p.Thr493Ile), c.877_888del (p.Leu293_Ser296del) (wang2024hemodynamicandclinical pages 1-3).

4.3 Modifier genes / interacting pathways

• GDF2 (BMP9): mutations can reduce/abolish BMP9 plasma levels and show population frequency differences (European descent 0.8–1.2% vs Asian 6.7% in cited review) (guignabert2024pathologyandpathobiology pages 11-12). In the Taiwanese cohort, GDF2 variant carriers had lower circulating GDF2 (135.6 ± 36.2 pg/mL vs 267.8 ± 185.8 pg/mL; p=0.002) (wang2024hemodynamicandclinical pages 1-3).

4.4 Epigenetics / chromatin

Broad epigenetic discussion exists in PAH reviews, but HPAH-specific epigenetic mechanisms were not directly extractable from the current evidence set.

5. Environmental Information

Direct environmental/lifestyle risk factors specific to HPAH were not a focus of the retrieved 2023–2024 evidence set. However, multiple experimental studies and reviews emphasize multifactorial causation in PAH and “second hit” triggers (hypoxia, inflammation) that interact with genetic susceptibility (todesco2024pulmonaryhypertensioninduced pages 1-2, sanchezduffhues2023humanipscsas pages 11-13).

6. Mechanism / Pathophysiology

6.1 Central pathway concept: BMP/TGF-β imbalance

A 2024 review states: “Endothelial dysfunction is recognised as an initial trigger for PAH” (abstract quote) and emphasizes BMP signaling in maintaining endothelial integrity (li2024bonemorphogeneticprotein pages 1-2). Multiple PAH risk genes are within the BMP signaling pathway (BMPR2, ACVRL1, ENG, GDF2, SMAD9) (li2024bonemorphogeneticprotein pages 1-2). In BMPR2 mutation contexts, reduced antiproliferative BMP-Smad1/5/8 signaling and increased proproliferative TGF-β/Smad2/3 signaling are described (arvidsson2024…inflammatoryproteins pages 27-30).

6.2 Cellular processes and causal chain (evidence-backed)

1. Upstream trigger: Germline BMPR2 pathway dysfunction (haploinsufficiency/LOF) (li2024bonemorphogeneticprotein pages 1-2, eichstaedt2023geneticcounsellingand pages 2-3).
2. Early cellular dysfunction: Endothelial dysfunction with impaired barrier integrity and dysregulated growth-factor signaling (li2024bonemorphogeneticprotein pages 1-2).
3. Vascular remodeling: Increased PASMC/fibroblast proliferation and reduced apoptosis, neointima and plexiform lesions (eichstaedt2023geneticcounsellingand pages 2-3).
4. Hemodynamic consequence: Increased PVR and mPAP leading to RV hypertrophy, failure (eichstaedt2023geneticcounsellingand pages 1-2, li2024bonemorphogeneticprotein pages 1-2).

6.3 Mechanistic examples from recent experimental work (2023–2024)

• PASMC BMPR2–ARRB2 axis (2023): Smooth muscle–specific Bmpr2 knockout mice show increased proliferation and apoptosis resistance and impaired contractility, linked to pERK1/2–pP38–pSMAD2/3 signaling, ARRB2 upregulation, AKT activation and β-catenin (CTNNB1) nuclear signaling; reducing ARRB2 attenuated persistent PH in inducible BMPR2-loss mice (wang2023dysregulatedsmoothmuscle pages 1-3).
• Endothelial BMPR2 → DLL4/NOTCH1/PPARγ (2024): BMPR2 silencing in pulmonary artery endothelial cells activated AKT and suppressed DLL4; exogenous DLL4/NOTCH1 signaling induced PPARγ and reversed proliferation/EndoMT phenotypes in vitro; reduced DLL4 expression was observed in small pulmonary arteries of PAH patients (awad2024bmpr2lossactivates pages 1-2).

6.4 Suggested ontology terms (mechanisms)

• GO Biological Process: blood vessel remodeling (GO:0001974); smooth muscle cell proliferation (e.g., GO:0048661); regulation of apoptotic process (GO:0042981); endothelial to mesenchymal transition (EndoMT; GO term depends on curation); response to hypoxia.
• CL Cell types: endothelial cell (CL:0000115); vascular smooth muscle cell (CL:0000359) / smooth muscle cell (CL:0000192); fibroblast (CL:0000057).

7. Anatomical Structures Affected

• Primary: Pulmonary arterioles/small pulmonary arteries (pre-capillary pulmonary arteries) with remodeling and obliteration (arvidsson2024…inflammatoryproteins pages 27-30, li2024bonemorphogeneticprotein pages 1-2). Suggested UBERON: pulmonary artery (UBERON:0002012).
• Secondary: Right ventricle (hypertrophy/dysfunction/failure) (li2024bonemorphogeneticprotein pages 1-2, wang2024hemodynamicandclinical pages 1-3). Suggested UBERON: right ventricle (UBERON:0002084).

8. Temporal Development

• Onset: Variable; may be early (e.g., ACVRL1-associated PAH median onset 20 years) (eichstaedt2023geneticcounsellingand pages 3-4).
• Progression: Progressive vascular remodeling leading to right heart failure; diagnostic delay ~2.8 years in registry-based summary (eichstaedt2023geneticcounsellingand pages 1-2).

9. Inheritance and Population

9.1 Inheritance pattern

• Main pattern: autosomal dominant with incomplete penetrance (eichstaedt2023geneticcounsellingand pages 3-4).
• Sex-dimorphic penetrance for BMPR2: 42% women vs 14% men (eichstaedt2023geneticcounsellingand pages 3-4).
• Important related entity: PVOD/PCH due to autosomal recessive biallelic EIF2AK4 (eichstaedt2023geneticcounsellingand pages 3-4).

9.2 Epidemiology (recently summarized)

• PAH incidence: 2.5–7.5 per million per year; prevalence 15–50 per million (French and Scottish registry summary cited in consensus statement) (eichstaedt2023geneticcounsellingand pages 2-3).
• HPAH proportion: ~3% of all PAH (eichstaedt2023geneticcounsellingand pages 2-3, kovacs2024definitionclassificationand pages 15-17).
• Female predominance: 70–80% female across registries (eichstaedt2023geneticcounsellingand pages 2-3).

10. Diagnostics

10.1 Hemodynamic definition (current)

The WSPH/ERS diagnostic definitions in 2023–2024 sources specify: - Pulmonary hypertension: mPAP >20 mmHg (kovacs2024definitionclassificationand pages 2-3, lechartier2023updatedhemodynamicdefinition pages 1-2). - Pre-capillary PH: mPAP >20 mmHg, PAWP ≤15 mmHg, PVR >2 WU (kovacs2024definitionclassificationand pages 2-3, lechartier2023updatedhemodynamicdefinition pages 1-2).

10.2 Screening in high-risk/asymptomatic individuals

A 2024 WSPH/ERS definition/classification report recommends screening asymptomatic high-risk groups (including BMPR2 mutation carriers and first-degree relatives of HPAH patients) using annual echocardiography, ECG, and NT-proBNP/BNP (kovacs2024definitionclassificationand pages 15-17). The DETECT tool can be used in appropriately selected systemic sclerosis spectrum disorder patients (kovacs2024definitionclassificationand pages 15-17).

The DOLPHIN-GENESIS study images (screening protocol and tables) were retrieved and support that multimodality screening in unaffected BMPR2 carriers may reveal abnormalities not captured by echocardiography/NT-proBNP alone (toth2024deepphenotypingof media 2112358a, toth2024deepphenotypingof media 5effec66).

10.3 Genetic testing approach (real-world implementation)

The ERS genetics consensus statement recommends that idiopathic, anorexigen-induced, congenital heart disease-associated and heritable PAH patients “should be offered genetic counselling and testing with a gene panel including all disease genes for the condition” (abstract quote) (eichstaedt2023geneticcounsellingand pages 1-2). The 2024 WSPH/ERS classification report similarly suggests genetic counselling and testing be offered to idiopathic PAH, suspected HPAH, anorexigen-associated PAH, and PAH-CHD (kovacs2024definitionclassificationand pages 15-17).

Note: Laboratory-specific panel composition and GTR-listed tests were not retrieved in this run.

11. Outcome / Prognosis

Evidence in the retrieved sources supports that BMPR2 pathogenic variant carriers (on average) have worse hemodynamics and higher risk of death or lung transplantation (eichstaedt2023geneticcounsellingand pages 3-4). However, genotype-stratified 5-year/10-year survival statistics specific to HPAH were not present in the tool-retrieved corpus and are therefore not reported.

12. Treatment

12.1 Current applications (standard-of-care pathways)

PAH therapies developed prior to 2024 primarily target three pathways affecting vascular tone: endothelin-1, nitric oxide, and prostacyclin; these improve exercise capacity and delay clinical worsening but are not curative (li2024bonemorphogeneticprotein pages 1-2).

A consolidated treatment summary, including ontology suggestions, is provided here:

Table: This table summarizes evidence-backed PAH treatments relevant to heritable pulmonary arterial hypertension, including standard pathway-directed therapies, risk-based combination strategies, and newer activin-pathway targeting with sotatercept. It is useful for linking drug classes to mechanisms, real-world use, named trials, and ontology-style MAXO treatment annotations.

12.2 Emerging / recent developments (2023–2024)

• Sotatercept (ActRIIA-Fc ligand trap; activin/TGF-β pathway modulation): A 2024 review states sotatercept “was recently approved by the FDA as a treatment for PAH” (abstract quote) while mechanism and target cells remain incompletely understood (li2024bonemorphogeneticprotein pages 1-2). In a 2024 treatment/biomarker summary, PULSAR and STELLAR are reported to show reduced PVR and increased 6MWD on background therapy, with stated FDA approval in Q1 2024 and EMA approval in Q3 2024 (arvidsson2024…inflammatoryproteins pages 27-30).
• Clinical trial implementation: STELLAR trial registry record is available via ClinicalTrials.gov (NCT04576988) (NCT04576988 chunk 6).

13. Prevention

No primary prevention for HPAH is established in the retrieved evidence set. Evidence-backed prevention-relevant strategies include: - Genetic counseling and cascade screening of relatives when a pathogenic variant is identified (eichstaedt2023geneticcounsellingand pages 1-2, kovacs2024definitionclassificationand pages 15-17). - Regular surveillance (annual echo/ECG/NT-proBNP) in high-risk asymptomatic individuals (kovacs2024definitionclassificationand pages 15-17).

14. Other Species / Natural Disease

Naturally occurring HPAH in non-human species was not directly addressed in the retrieved evidence. The evidence base primarily concerns engineered rodent models and human iPSC-derived systems (todesco2024pulmonaryhypertensioninduced pages 1-2, sanchezduffhues2023humanipscsas pages 11-13).

15. Model Organisms and Experimental Models

15.1 Rodent genetic and “second-hit” models

• RPA occlusion + Bmpr2 mutation (rat; 2024): Right pulmonary artery occlusion induces acute and chronic pre-capillary PH; Bmpr2 mutant rats and males develop more severe disease with higher mortality, with increased IL-6 and decreased Gdf2 expression under chronic occlusion (todesco2024pulmonaryhypertensioninduced pages 1-2, todesco2024pulmonaryhypertensioninduced pages 2-3).
• SMC-specific Bmpr2 deletion + hypoxia (mouse; 2023): Hypoxia used as second hit leading to persistent PH with distal pulmonary artery muscularization; PASMC show hyperproliferation and apoptosis resistance; pathways include ERK/p38/SMAD2/3 and AKT/β-catenin with ARRB2 as a candidate mediator (wang2023dysregulatedsmoothmuscle pages 1-3).

15.2 Human iPSC-based disease modeling

A 2023 review highlights that “most rodent models of HPAH do not precisely recapitulate the disease pathology” (quote) and describes iPSC-derived vascular cells for humanized modeling, including CRISPR/Cas9-corrected isogenic controls that restored cell adhesion molecule levels and survival responses under stress (sanchezduffhues2023humanipscsas pages 11-13).

Expert interpretation and analysis (authoritative sources)

• 2023–2024 ERS/WSPH expert sources converge on three priorities for HPAH: (i) standardizing clinical gene validity and variant interpretation via expert curation, (ii) deploying genetic counseling/testing and high-risk surveillance as part of routine PAH care pathways, and (iii) moving beyond vasodilators toward pathobiology-directed therapies affecting proliferative signaling and remodeling (austin2024geneticsandprecision pages 1-2, kovacs2024definitionclassificationand pages 15-17, li2024bonemorphogeneticprotein pages 1-2, arvidsson2024…inflammatoryproteins pages 27-30).

References (URLs; publication dates embedded in citations)

Key sources used include: - Eichstaedt et al., ERS Genetic counselling and testing consensus statement (Oct 2023): https://doi.org/10.1183/13993003.01471-2022 (eichstaedt2023geneticcounsellingand pages 1-2, eichstaedt2023geneticcounsellingand pages 3-4, eichstaedt2023geneticcounsellingand pages 2-3) - Kovacs et al., WSPH/ERS definition/classification/diagnosis (Aug 2024): https://doi.org/10.1183/13993003.01324-2024 (kovacs2024definitionclassificationand pages 2-3, kovacs2024definitionclassificationand pages 15-17) - Li & Quigley, BMP signaling review (May 2024): https://doi.org/10.1042/BST20231547 (li2024bonemorphogeneticprotein pages 1-2) - Todesco et al., RPA occlusion + Bmpr2 rat model (Jul 2024): https://doi.org/10.1161/jaha.124.034621 (todesco2024pulmonaryhypertensioninduced pages 1-2, todesco2024pulmonaryhypertensioninduced pages 2-3) - Wang et al., WES cohort (Feb 2024): https://doi.org/10.3390/ijms25052734 (wang2024hemodynamicandclinical pages 1-3) - Wang et al., BMPR2–ARRB2 PASMC axis (Mar 2023): https://doi.org/10.1161/circresaha.121.320541 (wang2023dysregulatedsmoothmuscle pages 1-3) - Awad et al., BMPR2–DLL4/NOTCH1/PPARγ (May 2024): https://doi.org/10.3390/ijms25105403 (awad2024bmpr2lossactivates pages 1-2) - STELLAR trial record: https://clinicaltrials.gov/study/NCT04576988 (NCT04576988) (NCT04576988 chunk 6)

Evidence limitations (transparency)

• Specific Orphanet/OMIM/ICD/MeSH identifiers and detailed long-term survival statistics were not accessible in the current tool-retrieved corpus and are therefore not included.
• Some treatment summaries (e.g., approvals/timing) come from a non-journal text source retrieved as “Unknown journal”; these were included only where explicit statements were present and triangulated with peer-reviewed reviews where possible (arvidsson2024…inflammatoryproteins pages 27-30, li2024bonemorphogeneticprotein pages 1-2).

References

1. (eichstaedt2023geneticcounsellingand pages 2-3): Christina A. Eichstaedt, Catharina Belge, Wendy K. Chung, Stefan Gräf, Ekkehard Grünig, David Montani, Rozenn Quarck, Jair A. Tenorio-Castano, Florent Soubrier, Richard C. Trembath, and Nicholas W. Morrell. Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the international consortium for genetic studies in pah. The European Respiratory Journal, 61:2201471, Oct 2023. URL: https://doi.org/10.1183/13993003.01471-2022, doi:10.1183/13993003.01471-2022. This article has 66 citations.

2. (kovacs2024definitionclassificationand pages 15-17): Gabor Kovacs, Sonja Bartolome, Christopher P. Denton, Michael A. Gatzoulis, Sue Gu, Dinesh Khanna, David Badesch, and David Montani. Definition, classification and diagnosis of pulmonary hypertension. The European Respiratory Journal, 64:2401324, Aug 2024. URL: https://doi.org/10.1183/13993003.01324-2024, doi:10.1183/13993003.01324-2024. This article has 434 citations.

3. (li2024bonemorphogeneticprotein pages 1-2): Wei Li and Kate Quigley. Bone morphogenetic protein signalling in pulmonary arterial hypertension: revisiting the bmprii connection. Biochemical Society Transactions, 52:1515-1528, May 2024. URL: https://doi.org/10.1042/bst20231547, doi:10.1042/bst20231547. This article has 28 citations and is from a peer-reviewed journal.

4. (arvidsson2024…inflammatoryproteins pages 27-30): M Arvidsson. … inflammatory proteins as biomarkers for diagnosis, differentiation, and risk assessment in pulmonary arterial hypertension-utilizing lund cardio pulmonary …. Unknown journal, 2024.

5. (eichstaedt2023geneticcounsellingand pages 1-2): Christina A. Eichstaedt, Catharina Belge, Wendy K. Chung, Stefan Gräf, Ekkehard Grünig, David Montani, Rozenn Quarck, Jair A. Tenorio-Castano, Florent Soubrier, Richard C. Trembath, and Nicholas W. Morrell. Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the international consortium for genetic studies in pah. The European Respiratory Journal, 61:2201471, Oct 2023. URL: https://doi.org/10.1183/13993003.01471-2022, doi:10.1183/13993003.01471-2022. This article has 66 citations.

6. (OpenTargets Search: pulmonary arterial hypertension): Open Targets Query (pulmonary arterial hypertension, 32 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

7. (kovacs2024definitionclassificationand pages 2-3): Gabor Kovacs, Sonja Bartolome, Christopher P. Denton, Michael A. Gatzoulis, Sue Gu, Dinesh Khanna, David Badesch, and David Montani. Definition, classification and diagnosis of pulmonary hypertension. The European Respiratory Journal, 64:2401324, Aug 2024. URL: https://doi.org/10.1183/13993003.01324-2024, doi:10.1183/13993003.01324-2024. This article has 434 citations.

8. (wang2024hemodynamicandclinical pages 1-3): Mei-Tzu Wang, Ken-Pen Weng, Sheng-Kai Chang, Wei-Chun Huang, and Lee-Wei Chen. Hemodynamic and clinical profiles of pulmonary arterial hypertension patients with gdf2 and bmpr2 variants. International Journal of Molecular Sciences, 25:2734, Feb 2024. URL: https://doi.org/10.3390/ijms25052734, doi:10.3390/ijms25052734. This article has 9 citations.

9. (todesco2024pulmonaryhypertensioninduced pages 1-2): Alban Todesco, Julien Grynblat, Kouamé Kan Firmin Akoumia, Damien Bonnet, Pedro Mendes‐Ferreira, Stéphane Morisset, Denis Chemla, Marilyne Levy, Mathilde Méot, Sophie‐Guiti Malekzadeh‐Milani, Birger Tielemans, Benoit Decante, Carine Vastel‐Amzallag, Paul Habert, Maria‐Rosa Ghigna, Marc Humbert, David Montani, David Boulate, and Frédéric Perros. Pulmonary hypertension induced by right pulmonary artery occlusion: hemodynamic consequences of bmpr2 mutation. Journal of the American Heart Association, Jul 2024. URL: https://doi.org/10.1161/jaha.124.034621, doi:10.1161/jaha.124.034621. This article has 4 citations.

10. (wang2023dysregulatedsmoothmuscle pages 1-3): Lingli Wang, Jan-Renier Moonen, Aiqin Cao, Sarasa Isobe, Caiyun G. Li, Nancy F. Tojais, Shalina Taylor, David P. Marciano, Pin-I. Chen, Mingxia Gu, Dan Li, Rebecca L. Harper, Nesrine El-Bizri, Yu-Mee Kim, Kryn Stankunas, and Marlene Rabinovitch. Dysregulated smooth muscle cell bmpr2–arrb2 axis causes pulmonary hypertension. Circulation Research, 132:545-564, Mar 2023. URL: https://doi.org/10.1161/circresaha.121.320541, doi:10.1161/circresaha.121.320541. This article has 56 citations and is from a highest quality peer-reviewed journal.

11. (eichstaedt2023geneticcounsellingand pages 3-4): Christina A. Eichstaedt, Catharina Belge, Wendy K. Chung, Stefan Gräf, Ekkehard Grünig, David Montani, Rozenn Quarck, Jair A. Tenorio-Castano, Florent Soubrier, Richard C. Trembath, and Nicholas W. Morrell. Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the international consortium for genetic studies in pah. The European Respiratory Journal, 61:2201471, Oct 2023. URL: https://doi.org/10.1183/13993003.01471-2022, doi:10.1183/13993003.01471-2022. This article has 66 citations.

12. (lechartier2023updatedhemodynamicdefinition pages 1-2): Benoit Lechartier, Mithum Kularatne, Xavier Jaïs, Marc Humbert, and David Montani. Updated hemodynamic definition and classification of pulmonary hypertension. Seminars in Respiratory and Critical Care Medicine, 44:721-727, Aug 2023. URL: https://doi.org/10.1055/s-0043-1770115, doi:10.1055/s-0043-1770115. This article has 8 citations and is from a peer-reviewed journal.

13. (guignabert2024pathologyandpathobiology pages 11-12): Christophe Guignabert, Jurjan Aman, Sébastien Bonnet, Peter Dorfmüller, Andrea J. Olschewski, Soni Pullamsetti, Marlene Rabinovitch, Ralph T. Schermuly, Marc Humbert, and Kurt R. Stenmark. Pathology and pathobiology of pulmonary hypertension: current insights and future directions. The European Respiratory Journal, 64:2401095, Aug 2024. URL: https://doi.org/10.1183/13993003.01095-2024, doi:10.1183/13993003.01095-2024. This article has 155 citations.

14. (sanchezduffhues2023humanipscsas pages 11-13): Gonzalo Sánchez-Duffhues and Christian Hiepen. Human ipscs as model systems for bmp-related rare diseases. Cells, 12:2200, Sep 2023. URL: https://doi.org/10.3390/cells12172200, doi:10.3390/cells12172200. This article has 11 citations.

15. (awad2024bmpr2lossactivates pages 1-2): Keytam S. Awad, Shuibang Wang, Edward J. Dougherty, Ali Keshavarz, Cumhur Y. Demirkale, Zu Xi Yu, Latonia Miller, Jason M. Elinoff, and Robert L. Danner. Bmpr2 loss activates akt by disrupting dll4/notch1 and pparγ signaling in pulmonary arterial hypertension. International Journal of Molecular Sciences, 25:5403, May 2024. URL: https://doi.org/10.3390/ijms25105403, doi:10.3390/ijms25105403. This article has 11 citations.

16. (toth2024deepphenotypingof media 2112358a): Eszter N. Tóth, Lucas R. Celant, Marili Niglas, Samara Jansen, Jelco Tramper, Nicoleta Baxan, Ali Ashek, Jeroen N. Wessels, J. Tim Marcus, Lilian J. Meijboom, Arjan C. Houweling, Esther J. Nossent, Jurjan Aman, Julien Grynblat, Frédéric Perros, David Montani, Anton Vonk Noordegraaf, Lan Zhao, Frances S. de Man, and Harm Jan Bogaard. Deep phenotyping of unaffected carriers of pathogenic bmpr2 variants screened for pulmonary arterial hypertension. The European Respiratory Journal, 64:2400442, Jul 2024. URL: https://doi.org/10.1183/13993003.00442-2024, doi:10.1183/13993003.00442-2024. This article has 11 citations.

17. (toth2024deepphenotypingof media 5effec66): Eszter N. Tóth, Lucas R. Celant, Marili Niglas, Samara Jansen, Jelco Tramper, Nicoleta Baxan, Ali Ashek, Jeroen N. Wessels, J. Tim Marcus, Lilian J. Meijboom, Arjan C. Houweling, Esther J. Nossent, Jurjan Aman, Julien Grynblat, Frédéric Perros, David Montani, Anton Vonk Noordegraaf, Lan Zhao, Frances S. de Man, and Harm Jan Bogaard. Deep phenotyping of unaffected carriers of pathogenic bmpr2 variants screened for pulmonary arterial hypertension. The European Respiratory Journal, 64:2400442, Jul 2024. URL: https://doi.org/10.1183/13993003.00442-2024, doi:10.1183/13993003.00442-2024. This article has 11 citations.

18. (NCT04576988 chunk 6): A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR). Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA. 2021. ClinicalTrials.gov Identifier: NCT04576988

19. (todesco2024pulmonaryhypertensioninduced pages 2-3): Alban Todesco, Julien Grynblat, Kouamé Kan Firmin Akoumia, Damien Bonnet, Pedro Mendes‐Ferreira, Stéphane Morisset, Denis Chemla, Marilyne Levy, Mathilde Méot, Sophie‐Guiti Malekzadeh‐Milani, Birger Tielemans, Benoit Decante, Carine Vastel‐Amzallag, Paul Habert, Maria‐Rosa Ghigna, Marc Humbert, David Montani, David Boulate, and Frédéric Perros. Pulmonary hypertension induced by right pulmonary artery occlusion: hemodynamic consequences of bmpr2 mutation. Journal of the American Heart Association, Jul 2024. URL: https://doi.org/10.1161/jaha.124.034621, doi:10.1161/jaha.124.034621. This article has 4 citations.

20. (austin2024geneticsandprecision pages 1-2): Eric D. Austin, Micheala A. Aldred, Mona Alotaibi, Stefan Gräf, William C. Nichols, Richard C. Trembath, and Wendy K. Chung. Genetics and precision genomics approaches to pulmonary hypertension. The European Respiratory Journal, 64:2401370, Aug 2024. URL: https://doi.org/10.1183/13993003.01370-2024, doi:10.1183/13993003.01370-2024. This article has 59 citations.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01
• Edison artifact artifact-02
• Edison artifact artifact-03